Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is the third most common cancer in the world and is the second leading cause of cancer-related deaths. Several mutations are involved in the development of CRC. The prognostic significance of the KRAS mutation has been discussed in many studies. We aimed to investigate the prognostic significance of the number of KRAS mutations in metastatic CRC (mCRC). Patients with mutations in the KRAS gene were included in the study. They were divided into 2 groups as single mutation and multiple mutations in the KRAS gene. For the study, 425 CRC patients were screened. KRAS mutation was positive in 191 patients (45%). One hundred ninety-one patients were included in the study, 171 patients (90%) had single mutations and 20 patients (10%) had multiple mutations. Median progression-free survival was 12.8 months in patients with multiple mutations, while it was 8.8 months in patients with single mutations (P: .05). The median overall survival of patients with multiple mutations was 40.7 months, while it was 22.7 months for patients with single mutations (P = .01) We found that the presence of multiple mutations in KRAS mutant patients was associated with better overall survival and progression-free survival than a single mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A retrospective review from Turkey reported no difference in the OS for patients with KRAS G12C and patients with other KRASm.58”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [58]
In the citing paper
“In contrast to these reports, 2 studies noted that the clinical outcomes in patients with KRAS G12C were either similar or superior to the outcomes observed in patients with other KRASm.”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583 · cited 1×
“Activating RAS mutations cause the deterioration of RAS protein activity; in this way GTPase activity is decreased, the protein becomes resistant to GTP hydrolysis by GTPase, resulting in a structurally active GTP-bound protein and a continuous growth stimulus.([7,8]) Therefore, oncogenic activity occurs.”
BackgroundRAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×
“There are 3 members of the RAS gene superfamily: KRAS, HRAS, and NRAS, and approximately 40% of CRCs contain KRAS mutations.([9,10]) While KRAS exon 2 mutations constitute the majority of KRAS mutations, exon 3 and exon 4 mutations constitute only 1% to 4% of CRCs.”
BackgroundKirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748 · cited 1×
“The multicenter RASCAL study([17]) investigated the prognostic significance of codon 12 and codon 13 mutations of exon 2, and found that only codon 12 mutations were independently associated with an increased risk of recurrence and death.”
BackgroundMolecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention
Colussi, D., Brandi, G., Bazzoli, F., & Ricciardiello, L. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140816365 · Cited by 429
Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw261 · Cited by 351
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290 · cited 1×
“Activating mutations in exons 2 and 3 have similar effects on RAS GTPase activity, whereas exon 4 mutations increase GDP to GTP exchange.([12]) KRAS point mutations occur particularly in codon 12 and to a lesser extent in codon 13 and 61.”
Background
Research works printed but not linked: 22
- 2013, Can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?, Genet Med, 15, 517, 10.1038/gim.2012.184 · doi:10.1038/gim.2012.184
- Takayama, 2001, Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis, Gastroenterology, 121, 599, 10.1053/gast.2001.27203 · DOI · Paper page
- Vogelstein, 1988, Genetic alterations during colorectal-tumor development, N Engl J Med, 319, 525, 10.1056/NEJM198809013190901 · DOI · Paper page
- Bourne, 1991, The GTPase superfamily: conserved structure and molecular mechanism, Nature, 349, 117, 10.1038/349117a0 · DOI · Paper page
- Mor, 2006, Compartmentalized Ras/MAPK signaling, Annu Rev Immunol, 24, 771, 10.1146/annurev.immunol.24.021605.090723 · DOI · Paper page
- Lea, 2007, Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns, Carcinogenesis, 28, 1851, 10.1093/carcin/bgm176 · DOI
- Edkins, 2006, Recurrent KRAS codon 146 mutations in human colorectal cancer, Cancer Biol Ther, 5, 928, 10.4161/cbt.5.8.3251 · DOI · Paper page
- Bos, 1989, Ras oncogenes in human cancer: a review, Cancer Res, 49, 4682
- Peeters, 2015, Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials, Eur J Cancer, 51, 704, 10.1016/j.ejca.2015.05.017 · DOI · Paper page
- Cerottini, 1998, The type of K-ras mutation determines prognosis in colorectal cancer, Am J Surg, 175, 198, 10.1016/S0002-9610(97)00283-3 · DOI
- Samowitz, 2000, Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study, Cancer Epidemiol Biomarkers Prev, 9, 1193
- Yoon, 2014, KRAS codon 12 and 13 mutations in relation to disease- free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance), Clin Cancer Res, 20, 3033, 10.1158/1078-0432.CCR-13-3140 · DOI · Paper page
- Taieb, 2016, Prognostic effect of BRAF and KRAS mutations in patients with stage iii colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial, JAMA Oncol, 2, 643, 10.1001/jamaoncol.2015.5225 · DOI · Paper page
- Taieb, 2017, Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer, J Natl Cancer Inst, 109
- Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 · DOI · Paper page
- Andreyev, 2001, Kirsten ras mutations in patients with colorectal cancer: the ’RASCAL II’ study, Br J Cancer, 85, 692, 10.1054/bjoc.2001.1964 · DOI · Paper page
- Bazan, 2002, Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype, Ann Oncol, 13, 1438, 10.1093/annonc/mdf226 · DOI · Paper page
- Dinu, 2014, Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study, J Med Life, 7, 581
- Ergun, 2019, KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer, Expert Rev Mol Diagn, 19, 1131, 10.1080/14737159.2019.1693266 · DOI
- Karadayi, 2016, Molecular analysis of Kras and Nras mutations in a series of 720 patients for guiding the treatment of metastatic colorectal cancer in Turkey, J Clin Oncol, 34, e13115, 10.1200/JCO.2016.34.15_suppl.e13115 · DOI
- Guo, 2018, Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients, Sci Rep, 8, 6076, 10.1038/s41598-018-24306-1 · DOI
- Andreatos, 2016, From bench to bedside: clinical implications of KRAS status in patients with colorectal liver metastasis, Surg Oncol, 25, 332, 10.1016/j.suronc.2016.07.002 · DOI
Cited by
Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
Koulouridi, A., Karagianni, M., Messaritakis, I., Sfakianaki, M., Voutsina, A., Trypaki, M., Bachlitzanaki, M., Koustas, E., Karamouzis, M. V., Ntavatzikos, A., et al. (2022) · Cancers · doi:10.3390/cancers14143320 · Cited by 63
Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023) · The Oncologist · doi:10.1093/oncolo/oyad138 · Cited by 54
Metadata
- Authors
- Ucar, G., Ergun, Y., Aktürk Esen, S., Acikgoz, Y., Dirikoc, M., Esen, İ., Bal, Ö., & Uncu, D.
- Affiliations
- Department of Medical Oncology, Ankara City Hospital, Ankara
- Department of Internal Medicine, Yenimahalle Training and Education Hospital, Ankara, Turkey.
- ORCID
- Ucar, Gokhan
- Venue
- Medicine
- Published
- 2020-09-25
- Volume
- 99
- Issue
- 39
- Pages
- e22407
- ISSN
- 0025-7974
- 1536-5964
- Cited by
- 19
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer. https://app.cochat.ai/papers/10.1097/md.0000000000022407
- The paper
- Ucar, G., Ergun, Y., Aktürk Esen, S., Acikgoz, Y., Dirikoc, M., Esen, İ., Bal, Ö., & Uncu, D. (2020). Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer. Medicine. https://doi.org/10.1097/md.0000000000022407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.